ENDOTHELIN-1 VALUE IN CARDIOVASCULAR COMPLICATIONS DEVELOPMENT FORECASTING IN PATIENTS WITH DIABETES MELITUS TYPE 2 AND CORONARY ARTERY DISEASE*

Authors

  • Krapivko S. A. Kharkiv national medical university, Kharkiv, Ukraine
  • Dunayeva I. P. Kharkiv Postgraduate Medical Academy, Kharkiv, Ukraine
  • Kadykova O. I. Kharkiv national medical university, Kharkiv, Ukraine
  • Zolotaikina V. I. Харківський національний медичний університет, м. Харків, Україна

DOI:

https://doi.org/10.21856/j-PEP.2019.4.08

Keywords:

endothelin-1, nitrogen oxide metabolites, diabetes melitus, chronic heart failure, cardiovascular complications, сardiovascular complications risk

Abstract

On the basis of 98 patients inspection with chronic heart failure of ischemic genesis and diabetes melitus
type 2 an endothelin-1 influence and cardiovascular complications existence were studied. As a result of the conducted researches it is established that endothelin-1 level in patients with diabetes melitus type 2 and chronic
heart failure is higher, than in patients with chronic heart failure without diabetes melitus type 2. It was
found that blood glucose and glycose hemoglobin levels were significantly higher in patients with FC III than in
patients with FC I and FC II. Due to the fact that the cardiovascular complications risk development stratification concept in patients with diabetes mellitus type 2 and coronary artery disease involves a general strategy
of prevention, treatment and prognosis taking into account personal, medical and social characteristics of the
patient. The developed mathematical model of cardiovascular complications development forecasting has shown
endothelin-1 and nitrogen oxide metabolites value as cardiovascular risk markers

References

Islam MS. Adv Exp Med Biol 2018; 1067: 1-3 doi: http://doi.org/10. 1007/5584_2018_181.

Scuffham PA, Ball J, Horowitz JD, et al. Eur Heart J 2017; 38(30): 2340-2348. doi: http://doi.org/10.1093/eurheartj/ehx259.

Dupre ME, Gu D, Xu H, et al. J Am Heart Assoc 2017; 6(11). doi: http://doi.org/10.1161/JAHA.117.006290.

Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha SS. Heart Fail Rev 2018; 23(3): 445-459.doi: http://doi.org/10.1007/s10741-017-9666-8

Tate M, Grieve DJ, Ritchie RH. Clin Sci (Lond) 2017; 131(10): 897-915. doi: http://doi.org/10.1042/CS20160491.

Picard F, dos Santos P, Catargi B. Rev Prat 2013; 63(6): 759-764.

Camafort M. Endocrinol Nutr 2015; 62(7): 350-355. doi: http://doi.org/10.1016/j.endonu. 2015.06.004.

Zhang X, Zhao SP, Li XP, et al. Atherosclerosis 2000; 149(1): 19-24.

Stangl R, Dschietzig T, Richer C, et al. Circulation 2000; 102: 1132-1138.

Yokokawa K, tahara H, Kohno M, et al. Ann Intern Med 1991; 114: 213-215.

Ohkita M, Tawa M, Kitada K, Matsumura Y. J Pharmacol Sci 2012; 119(4): 302-313. doi: http://doi.org/10.1254/jphs.12r01cr.

Tesfamariam B, Brown ML, Cohen RA. J Clin Invest 1991; 87(5): 1643-1648.

Downloads

Published

2019-11-11

How to Cite

Krapivko, S. A., Dunayeva, I. P., Kadykova, O. I., & Zolotaikina, V. I. (2019). ENDOTHELIN-1 VALUE IN CARDIOVASCULAR COMPLICATIONS DEVELOPMENT FORECASTING IN PATIENTS WITH DIABETES MELITUS TYPE 2 AND CORONARY ARTERY DISEASE*. Problems of Endocrine Pathology, 70(4), 60-66. https://doi.org/10.21856/j-PEP.2019.4.08

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 > >>